{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.83","value":"3.40"},{"groupId":"OG001","spread":"7.83","value":"3.40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"The Neuropathy Impairment Score -Lower Limbs (NIS-LL) is the objective measurement of PNP symptoms. The degree of PNP will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03. The CTCAE is a 0-5 scale that assesses severity of neuropathy related to cancer therapy with higher scores meaning more symptoms A difference of 2 points between groups is considered significant. This measure will be performed at baseline and at 4 months.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.\n\nglutamine: Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.\n\nquality-of-life assessment: Ancillary studies","id":"OG000","title":"Arm I (Preventative Nutritional Supplementation)"},{"description":"Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.\n\nquality-of-life assessment: Ancillary studies\n\nplacebo: Given PO","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"All participants enrolled in study and given treatment.","reportingStatus":"POSTED","timeFrame":"up to 4 months from start of study","title":"Degree of Peripheral Neuropathy (PNP)","type":"PRIMARY","unitOfMeasure":"units on a scale"}